Using decision curve analysis, the addition of myoglobin predicted AKI with net benefit in range (5–11% + 17–40%, Fig. 3A) and (15–45%, Fig. 3B) in the first and second validated model, respectively, while CK did not add net benefit. Here, MB is linked to acute kidney injury.